Scripps Whittier Diabetes Institute
Trial Pipeline
Enhancing Digitally Delivered Diabetes Education With Real-Time CGM
NCT06296550
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
NCT05416060
Project Dulce for Arab Americans With Type 2 Diabetes
NCT05580536
ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes
NCT04933851
Pilot RCT Evaluating Clinical Outcomes of Using Undermyfork Mobile App With Dexcom G7
NCT06501612
Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes
NCT03130699
Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic
NCT03552107
Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being
NCT02723019
Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign
NCT03068273
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
What the Pipeline for Scripps Whittier Diabetes Institute Shows
According to the ClinicalTrials.gov registry, Scripps Whittier Diabetes Institute is linked to 9 US clinical trials across every stage of research activity. Of those, 4 studies are currently recruiting — about 44% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 56% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Scripps Whittier Diabetes Institute reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Scripps Whittier Diabetes Institute is Diabetes Mellitus, Type 2 with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.